Selective serotonin receptor inverse agonists as therapeutics for disease

• US 7,820,695 B2
• Filed: 05/21/2004
• Issued: 10/26/2010
• Est. Priority Date: 05/21/2004
• Status: Active Grant

• Current Assignee: Acadia Pharmaceuticals Inc.
• Original Assignee: Acadia Pharmaceuticals Inc.
• Inventors: Davis, Robert E., Brann, Mark R., Weiner, David M.
• Primary Examiner(s): Padmanabhan; Sreeni
• Assistant Examiner(s): Javanmard; Sahar
• Application Number:
  US10/850,819
• Publication Number:
  US 20050261340A1
• Time in Patent Office: 2,349 Days
• Field of Search: 514/224.5, 514/279, 514/595, 514/277, 514/317, 514/649
• US Class Current: 514/317
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions.

Claims

1. A pharmaceutical composition comprising a compound of Formula (I)

2. The pharmaceutical composition of claim 1, further comprising a physiologically acceptable carrier, diluent, or excipient, or a combination thereof.

6. The composition of claim 1, wherein the compound of formula (I) is the free base.

7. The composition of claim 1, wherein the composition is in a single unit dosage form.

8. The composition of claim 7, wherein the composition is in a single unit dosage form suitable for oral administration to a human.

9. The composition of claim 8, wherein the dosage form is solid.

10. The composition of claim 9, wherein the composition is in the form of a tablet or a capsule.

11. The composition of claim 10, wherein the composition is in the form of a tablet.

12. The composition of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is from about 0.1 mg to about 500 mg.

13. The composition of claim 1, wherein the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 40 mg.

3. A pharmaceutical composition comprising a compound of Formula (I)

4. The composition of claim 3, wherein the selective serotonin reuptake inhibitor is selected from the group consisting of bupropion, citalopram, duloxetine, escitalopram, fluvoxamine, nefazodone, paroxetine, sertaline, sibutramine, trazodone, and venlafaxine.

5. The pharmaceutical composition of claim 3, further comprising a physiologically acceptable carrier, diluent, or excipient, or a combination thereof.